Momenta Pharmaceuticals to Webcast Presentation at the UBS 2015 Global Healthcare Conference
12. Mai 2015 16:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 12, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at the Bank of America Merrill Lynch 2015 Health Care Conference
06. Mai 2015 16:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 6, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals to Webcast Presentation at the Deutsche Bank 40th Annual Health Care Conference
01. Mai 2015 16:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Reports First Quarter 2015 Financial Results
01. Mai 2015 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., May 1, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter ended March 31, 2015.
For the first quarter...
Momenta Presents Key Glatopa(TM) (glatiramer acetate injection) Data at American Academy of Neurology Annual Meeting
20. April 2015 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 20, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Data Presentations on Glatopa(TM) (glatiramer acetate injection) at the American Academy of Neurology's (AAN) 2015 Annual Meeting
17. April 2015 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 17, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces Conference Call Details Regarding FDA Approval for Glatopa(TM) (glatiramer acetate injection)
16. April 2015 12:53 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 16, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...
Momenta Pharmaceuticals Announces FDA Approval of ANDA for Glatopa(TM) (glatiramer acetate injection), the First Substitutable Generic for COPAXONE(R) (glatiramer acetate injection) 20mg
16. April 2015 12:30 ET
|
Momenta Pharmaceuticals
First generic multiple sclerosis product approved in the United States
Approval triggers $10 million milestone payment to Momenta
CAMBRIDGE, Mass., April 16, 2015 (GLOBE NEWSWIRE) --...
Momenta Pharmaceuticals Announces Date of First Quarter 2015 Financial Results Conference Call and Webcast
15. April 2015 08:00 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., April 15, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will...
Momenta Pharmaceuticals Announces Publication Revealing Development of a Novel Process to Generate High-Quality Hyper-sialylated IVIg Drug Candidate in PNAS
02. März 2015 15:34 ET
|
Momenta Pharmaceuticals
CAMBRIDGE, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today...